Manuscripts
August 26, 2024
Treatment intensification in metastatic hormone-sensitive prostate cancer: An analysis of real-world practice patterns from the CancerLinQ database
Urologic Oncology
Eule CJ et al
June 25, 2024
EGFR mutation testing, treatment and survival in stage I–III non-small-cell lung cancer: CancerLinQ Discovery database retrospective analysis
Future Oncology
Muthusamy B et al
June 19, 2024
Real-world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer
Cancer Medicine
Sukumar JS et al
June 19, 2024
The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer
NPJ Breast Cancer
Johnson KCC et al
March 28, 2024
Seeking American Society of Clinical Oncology-Quality Oncology Practice Initiative (ASCO-QOPI) certification in a northern New England rural health system and cancer care network
Learning Health Systemas
Perrey HM et al
January 10, 2024
Prognosis and conditional survival among women with newly diagnosed ovarian cancer
Gynecologic Oncology
Szamreta EA et al
October 18, 2023
Natural history and real-world treatment outcomes for non-small cell lung cancer patients with EGFR exon 20 insertion mutation: An IASLC- ASCO CancerLinQ study
JTO Clinical & Research Reports
Behera M et al
September 20, 2023
Real-world pitfalls of analyzing real-world data: A cautionary note and path forward
JCO Clinical Cancer Informatics
Cooper JD et al
August 30, 2023
Prognostic impact of second primary malignancies in multiple myeloma: An ASCO CancerLinQ Discovery analysis of the modern era [CORRESPONDENCE]
American Journal of Hematology
Gibson S et al
Abstracts
May 23, 2024
Electronic clinical quality measure (eCQM) concordance and quality care disparities among patients with breast cancer (BC).
ASCO Annual Meeting 2024
Jones N et al
May 23, 2024
Predicting real-world overall survival for post-operative pancreatic ductal adenocarcinoma: An ASCO CancerLinQ Discovery analysis.
ASCO Annual Meeting 2024
Sohail Ahmed K et al
May 23, 2024
Disparities in patients with HER2-positive breast cancer receiving optimal treatment: Analysis of the real-world ASCO CancerLinQ dataset.
ASCO Annual Meeting 2024
Kantor O et al
May 1, 2024
MP51-18: Population-based trends and outcomes for cytoreductive nephrectomy for metastatic renal cell carcinoma in the United States
AUA Annual Meeting 2024
Wiesen B et al
May 1, 2024
MP31-17: Variation in genomic testing amongst localized prostate cancer patients undergoing radical prostatectomy or radiation therapy: Results from a population-based cohort
AUA Annual Meeting 2024
Wiesen B et al
January 29, 2024
Patterns of concurrent chemotherapy selection in US patients undergoing trimodality therapy for muscle-invasive bladder cancer
ASCO Genitourinary Cancers Symposium 2024
Callihan E et al
January 29, 2024
Real world evidence comparison of first-line (1L) immune-oncology(IO)/tyrosine kinase inhibitor (TKI) vs. IO/IO combination therapy in renal cell carcinoma (RCC)
ASCO Genitourinary Cancers Symposium 2024
Bolan P et al
December 7, 2023
Disparities in genetic testing patterns and positivity among patients with breast cancer in the CancerLINQ real-world oncology database
San Antonio Breast Cancer Symposium 2023
Kantor O et al
October 27, 2023
Uptake and efficacy of immuno-oncology combinations in metastatic renal cell carcinoma in the United States: Evidence from the ASCO CancerLinQ Discovery database
ASCO Quality Care Symposium 2023
Vento J et al
